Statement: All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration.
Primary_evidence: Outcome Measurement:    Percentage of Participants by Preferred Method of Drug Administration   The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant. Participants were asked, "All things considered, which method of administration did you prefer?" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported.   Time frame: Week 24 Results 1:    Arm/Group Title: Cohort 1: SC (SID) Then IV Herceptin   Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin was administered via SID, and during Cycles 5 to 8, IV Herceptin was given. In the continuation period, participants received IV Herceptin for up to 10 remaining cycles. Administration was performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP. The SC dose was 600 mg for all cycles where SC Herceptin was given, and the IV dose was 6 mg/kg for all cycles where IV Herceptin was given.   Overall Number of Participants Analyzed: 117   Measure Type: Number   Unit of Measure: percentage of participants  SC Herceptin: 95.7   IV Herceptin: 4.3   No Preference: 0.0 Results 2:    Arm/Group Title: Cohort 1: IV Then SC (SID) Herceptin   Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin was given, and during Cycles 5 to 8, SC Herceptin was administered via SID. In the continuation period, participants received IV Herceptin for up to 10 remaining cycles. Administration was performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP. The IV dose was a loading dose of 8 mg/kg in Cycle 1 for de novo participants who started Herceptin treatment in the study, and a dose of 6 mg/kg for all subsequent cycles where IV Herceptin was given and for non-de novo participants. The SC dose was 600 mg for all cycles where SC Herceptin was given.   Overall Number of Participants Analyzed: 119   Measure Type: Number   Unit of Measure: percentage of participants  SC Herceptin: 87.4   IV Herceptin: 9.2   No Preference: 3.4